Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...

Endpoint protection, often abbreviated as EPP, is a system designed to secure each endpoint of an enterprise network from potential cyber threats. It's a security approach that focuses on each device ...

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an ...

Q3 2025 Management View CEO Frank Bedu-Addo provided an update on advancing PDS0101 (Versamune HPV) in HPV16-positive recurrent and/or metastatic head and neck cancer, highlighting the completion of ...

Modern endpoint management is undergoing a transformation through automation. This webinar explores the practical journey ...

Strengthen your security stack with Microsoft Defender for Endpoint for advanced threat protection, detection, and real-time defense.

Current guidelines for the U.S. and Europe have a recommendation of class 2b, level of evidence B or C for LAAO in patients ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more Bad actors continue to capitalize on the ...

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction ...

Trodelvy did not meet the primary endpoint of progression-free survival in the ASCENT-07 trial for HR-positive, HER2-negative ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Attackers strike at businesses with identity theft as their top goal.

In this video from the American Academy of Ophthalmology meeting, Philip J. Ferrone, MD, discusses the TEASE-2 trial results in treating Stargardt disease with gildeuretinol.